Starpharma deal with Dow out of the bag

By Renate Krelle
Thursday, 20 January, 2005

Starpharma (ASX:SPL) was forced into a trading halt this morning after a report in Melbourne broadsheet The Age revealed that Starpharma's US subsidiary Dendritic Nanotechnologies (DNT) was about to consummate an intellectual property deal with US giant Dow Chemical company.

At time of writing, Starpharma had not yet provided the market with clarification on the deal. It reportedly involves the transfer of approximately 200 of Dow's nanotechnology patents, including patents in the dendrimer field in which Starpharma specialises. Dow was to receive an equity stake in DNT as consideration.

In November, Starpharma reported positive preliminary results from the Phase I clinical trial on its dendrimer-based vaginal microbicide Vivagel.

Content from other channels on our network

Partnership to develop lower-emission titanium production

Refinery transforms CO2 into useable raw materials

Siemens expands Fusesaver manufacturing facility

BESS project provides long-duration battery for NSW

Lessons in long-distance telemetry

Innovating chemical dosing & dilution in aged care

A shift in clinical practice: optimal antibiotics for golden staph bloodstream infections

The rise of non-clinical, community-led safe spaces: how lived experience is reshaping suicide prevention

Mandatory VR violence training for nursing students

National virtual care standards on the way

Poultry and egg producers in lockdown as avian flu detected in WA

RMIT Food Innovation Hub to help advance food processing technology

Vacuum Cooling. The fix to your cooling bottleneck.

SAVE FOOD Initiative award winners from interpack

WA dog food manufacturer seals SE Asia export deal

Starpharma deal with Dow out of the bag

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Australia announces $7.2m diphtheria outbreak response package

Content from other channels on our network